<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Crémieux, Anne-Claude</dc:creator>
  <dc:creator>Dinh, Aurélien</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:creator>Mouton, William</dc:creator>
  <dc:creator>Tattevin, Pierre</dc:creator>
  <dc:creator>Ghout, Idir</dc:creator>
  <dc:creator>Jayol, Aurélie</dc:creator>
  <dc:creator>Aimer, Omar</dc:creator>
  <dc:creator>Gatin, Laure</dc:creator>
  <dc:creator>Verdier, Marie-Clémence</dc:creator>
  <dc:creator>Saleh-Mghir, Azzam</dc:creator>
  <dc:creator>Laurent, Frédéric</dc:creator>
  <dc:date>2019-09-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Objectives: In a new experimental model of carbapenemase-producing Klebsiella  pneumoniae osteomyelitis we evaluated the efficacy of colistin alone and in various  combinations and examined the emergence of colistin-resistant strains and cross- resistance to host defence peptides (HDPs).Methods: KPC-99YC is a clinical strain  with intermediate susceptibility to meropenem (MIC = 4 mg/L) and full susceptibility to  gentamicin, colistin and tigecycline (MICs = 1 mg/L) and fosfomycin (MIC = 32 mg/L).  Time–kill curves were performed at 4× MIC. Osteomyelitis was induced in rabbits by  tibial injection of 2 × 108 cfu. Treatment started 14 days later for 7 days in seven  groups: (i) control; (ii) colistin; (iii) colistin + gentamicin; (iv) colistin + tigecycline; (v)  colistin + meropenem; (vi) colistin + meropenem + gentamicin; and (vii) colistin +  fosfomycin.Results: In vitro, colistin was rapidly bactericidal, but regrowth occurred  after 9 h. Combinations of colistin with meropenem or fosfomycin were synergistic,  whereas combination with tigecycline was antagonistic. In vivo, colistin alone was not  effective. Combinations of colistin with meropenem or fosfomycin were bactericidal (P  &lt; 0.001) and the addition of gentamicin enhanced the efficacy of colistin + meropenem  (P = 0.025). Tigecycline reduced the efficacy of colistin (P = 0.007). Colistin-resistant  strains emerged in all groups except colistin + fosfomycin and two strains showed  cross-resistance to HDP LL-37.Conclusions: In this model, combinations of colistin  plus meropenem, with or without gentamicin, or colistin plus fosfomycin were the only  effective therapies. The combination of colistin and tigecycline should be administered  with caution, as it may be antagonistic in vitro and in vivo.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/308210</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308210/files/nor_eca.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308210/files/nor_eca_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkz257</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of Antimicrobial Chemotherapy. - 2019, vol. 74, no. 9, p. 2666–2675</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
